{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-23-000258","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.395751+00:00","generated_at":"2026-06-19T02:31:41.971829+00:00","sec_items":["1.01","3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Enochian BioSciences receives Nasdaq notice for delayed Form 10-Q filing and amends convertible notes","bullets":["Amended and restated two $600,000 convertible notes with Paseco ApS, extending maturity to February 28, 2024 and securing obligations.","Amended a $5,000,000 promissory note from March 2020 to secure obligations under a new security agreement.","Entered into a security agreement granting Paseco ApS a first priority security interest in all of Enochian's assets.","Received Nasdaq notice on February 16, 2023 for non-compliance due to delayed filing of Form 10-Q for period ended December 31, 2022.","Nasdaq previously accepted compliance plan; deadline to regain compliance is April 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-23-000258","json":"https://secwatch.observer/filing/0001731122-23-000258.json","markdown":"https://secwatch.observer/filing/0001731122-23-000258.md","text":"https://secwatch.observer/filing/0001731122-23-000258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/e4441_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:31:41.971829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c18daeb162308c1a40e88c8dd1c3c9a318e0c4a5","claim":"Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).","evidence_excerpt":"February 16, 2023, the Company received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Co","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"late filing"},{"label":"Rules","value":"5250(c)(1)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"5c01c3ee2e99a75f17b7c90342a430341e0a5ed6","claim":"Lunai Bioworks Inc. amended Amended and Restated February Notes with Paseco ApS valued at $600,000 (effective 2022-12-30).","evidence_excerpt":"On February 16, 2023, the Company amended and restated those two certain convertible promissory notes between the Company and Paseco ApS (the “ Holder ”) dated February 6, 2020, each in the principal amount of $600,000 (the “ February Notes ”) by entering into two amended and restated secured convertible promissory notes, each with an effective date of December 30, 2022 and each in the principal amount of $600,000 (the “ Amended and Restated February Notes ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Paseco ApS"},{"label":"Value","value":"$600,000"},{"label":"Effective","value":"2022-12-30"}],"fact_type":"material_agreement"},{"claim_id":"adc0d3ccca0867eb9072a1815b96f894cfa54d89","claim":"Lunai Bioworks Inc. amended Amendment to the March Note with Paseco ApS valued at $5,000,000 (effective 2022-12-30).","evidence_excerpt":"On February 16, 2023, the Company amended that certain promissory note dated March 30, 2020 in the principal amount of $5,000,000 between the Company and the Holder (the “ March Note ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Paseco ApS"},{"label":"Value","value":"$5,000,000"},{"label":"Effective","value":"2022-12-30"}],"fact_type":"material_agreement"},{"claim_id":"ffe2cf821c63483e68c9a7cbb4772dd54d70845e","claim":"Lunai Bioworks Inc. entered into Security Agreement with Paseco ApS (effective 2022-12-30).","evidence_excerpt":"On February 16, 2023, the Company entered into a security agreement between the Company and the Holder, effective as of December 30, 2022 (the “ Security Agreement ”) under which the Company pledged and granted the Holder a first priority security interest in and lien upon all of the Company’s wholly-owned assets as collateral security for the prompt payment in full of the principal amounts of the February Notes and the March Note when due.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Paseco ApS"},{"label":"Effective","value":"2022-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}